Skip to main content

News

You are here

UM Ventures Congratulates UM Baltimore Licensee, Hemerus Medical, LLC, on FDA Approval of SOLX® Whole Blood Collection System; Hemerus Acquired by Haemonetics Corporation

Saturday, May 25, 2013

Haemonetics Corporation (NYSE:HAE) announced that it has completed its previously announced acquisition of the assets of Hemerus Medical, LLC ("Hemerus"), a Minnesota-based company that develops innovative technologies for the collection of whole blood and for the processing and storage of blood components.

Haemonetics recently learned that the U.S. FDA approved Hemerus' New Drug Application for the SOLX® whole blood collection system for eight hour storage of whole blood. Hemerus previously received CE Marking (Conformite Europeenne) in the European Union to market SOLX as the world's first 56-day red blood cell storage solution. Haemonetics paid $23 million cash at the April 30 closing and, including $1 million paid early in fiscal 2013, has paid $24 million to date. Haemonetics will pay an additional $3 million upon a further FDA approval of the SOLX solution for 24 hour storage of whole blood prior to processing, and will pay up to $14 million on future sales of SOLX-based products.

Read release from Haemonetics